In re King Pharmaceuticals, Inc. Securities Litigation

http://www.kingsecuritiessettlement.com/

Court: United States District Court, Eastern District of Tennessee, Greenville
Case Number: 03-cv-077
Judge: Hon. Thomas W. Phillips
Class Period: 02/16/1999 - 03/10/2003
Case Contacts: John C. Browne

Securities fraud class action brought on behalf of purchasers of King Pharmaceuticals, Inc. ("King") common stock on the open market from February 16, 1999 through March 10, 2003 ("Class Period"), including all persons who acquired King common stock pursuant to, or traceable to King's public offering in November 2001 and any persons or entities who exchanged their shares of Jones Pharma, Inc. for shares of King in August 2000.

King is a pharmaceutical company that develops, manufactures, markets and sells branded prescription pharmaceutical products.  Plaintiffs allege that during the Class Period, King failed to properly reimburse Medicaid and other government pricing programs over $46.5 million.  Plaintiffs also allege that King manufactured sales to a related party, the King Benevolent Fund, an entity controlled by King's management, late in the quarter to ensure that King met its sales and earnings targets for the quarter.  King failed to disclose these transactions until after March 11, 2003 when it announced that the SEC was investigating the Company.

Court Grants Final Approval of $38.25 Million Settlement in King Pharmaceuticals, Inc. Securities Litigation

On January 9, 2007, a settlement fairness hearing was held, during which time the Court granted final approval of the settlement and plan of allocation and issued a Final Judgment and Order of Dismissal with Prejudice, ending this litigation and relinquishing all claims against Defendants.

In order to have been eligible to share in the benefits of the settlement, class members should have submitted a completed and signed Proof of Claim form postmarked no later than February 8, 2007. 

Other Cases of Interest

  • Venator Materials PLC
    Southern District of Texas, Houston Division John C. Browne, Michael D. Blatchley, Nicholas Gersh
  • Allergan, Inc. (Drug Pricing)
    District of New Jersey John C. Browne, Lauren McMillen Ormsbee, Michael Mathai, Nicholas Gersh, Erika Connolly
  • Citigroup, Inc.
    Southern District of New York John C. Browne, David Wales, John Rizio-Hamilton, Jeremy P. Robinson, Laura Lefkowitz, Catherine E. van Kampen
  • ComScore, Inc.
    Southern District of New York John C. Browne, Jai K. Chandrasekhar, Jesse L. Jensen, Kate Aufses, Alex Dickin, Catherine E. van Kampen
  • GT Advanced Technologies Inc.
    District of New Hampshire John C. Browne, Lauren McMillen Ormsbee, Catherine E. van Kampen
  • Boeing Company
    Northern District of Illinois Eastern Division John C. Browne, Gerald H. Silk, Adam Hollander, Abe Alexander, Scott R. Foglietta, James M. Fee, Katherine M. Sinderson, Reiko Cyr
  • Stericycle, Inc.
    District of Illinois Eastern Division John C. Browne, Adam H. Wierzbowski
  • Mohawk Industries, Inc.
    Northern District of Georgia John C. Browne, Jonathan D. Uslaner, Richard D. Gluck, Lauren M. Cruz, Alexander T. Payne
  • AnaptysBio, Inc.
    Southern District of California John C. Browne, Hannah Ross, Lauren McMillen Ormsbee, Jonathan D. Uslaner, Alexander T. Payne
  • Energy Transfer LP
    Eastern District of Pennsylvania John C. Browne, Michael D. Blatchley, Hannah Ross, Adam H. Wierzbowski, Michael Mathai, James M. Fee